ID   MPanc-96
AC   CVCL_7165
SY   Mpanc-96; MPanc96; mPanc96; MPANC96
DR   ATCC; CRL-2380
DR   BioSample; SAMN03151612
DR   cancercelllines; CVCL_7165
DR   Cosmic; 913309
DR   Cosmic; 1299303
DR   Cosmic; 1571780
DR   GEO; GSM784704
DR   IARC_TP53; 20487
DR   Progenetix; CVCL_7165
DR   Wikidata; Q54906434
RX   DOI=10.4172/jpb.1000057;
RX   PubMed=9185703;
RX   PubMed=15367885;
RX   PubMed=20143388;
CC   Problematic cell line: Contaminated. Shown to be a AsPC-1 derivative (PubMed=20143388). Originally thought to originate from a 67 year old male patient with a poorly differentiated primary pancreatic adenocarcinoma.
CC   Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00329.
CC   Population: Caucasian.
CC   Doubling time: 27 hours (PubMed=9185703).
CC   Sequence variation: Gene deletion; HGNC; 6844; MAP2K4; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Leu78Hisfs*41 (c.233_234delTC) (p.His93Profs*67, c.276_277delTC); ClinVar=VCV000977782; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Homozygous (PubMed=15367885).
CC   Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Arg100Thr (c.299G>C); Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys135Alafs*35 (c.403delT); ClinVar=VCV001069265; Zygosity=Heterozygous (PubMed=15367885).
CC   Omics: Proteome analysis by 2D-DE/MS.
CC   Misspelling: Mpan96; Cosmic=1299303.
CC   Discontinued: ATCC; CRL-2380; true.
CC   Derived from site: Metastatic; Ascites; UBERON=UBERON_0007795.
ST   Source(s): ATCC=CRL-2380
ST   Amelogenin: X
ST   CSF1PO: 10,13
ST   D13S317: 9,12
ST   D16S539: 11
ST   D5S818: 12
ST   D7S820: 12,13
ST   TH01: 7,9.3
ST   TPOX: 8,10
ST   vWA: 17
DI   NCIt; C9120; Pancreatic ductal adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0152 ! AsPC-1
SX   Female
AG   62Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 02-05-24; Version: 30
RX   DOI=10.4172/jpb.1000057;
RA   Yamada M., Fujii K., Koyama K., Hirohashi S., Kondo T.;
RT   "The proteomic profile of pancreatic cancer cell lines corresponding
RT   to carcinogenesis and metastasis.";
RL   J. Proteomics Bioinformatics 2:1-18(2009).
RX   PubMed=9185703; DOI=10.1002/(SICI)1097-0215(19970611)71:6<993::AID-IJC15>3.0.CO;2-7;
RA   Peiper M., Nagoshi M., Patel D., Fletcher J.A., Goegebuure P.S.,
RA   Eberlein T.J.;
RT   "Human pancreatic cancer cells (MPanc-96) recognized by autologous
RT   tumor-infiltrating lymphocytes after in vitro as well as in vivo tumor
RT   expansion.";
RL   Int. J. Cancer 71:993-999(1997).
RX   PubMed=15367885; DOI=10.1097/00006676-200410000-00004;
RA   Loukopoulos P., Kanetaka K., Takamura M., Shibata T., Sakamoto M.,
RA   Hirohashi S.;
RT   "Orthotopic transplantation models of pancreatic adenocarcinoma
RT   derived from cell lines and primary tumors and displaying varying
RT   metastatic activity.";
RL   Pancreas 29:193-203(2004).
RX   PubMed=20143388; DOI=10.1002/ijc.25242;
RA   Capes-Davis A., Theodosopoulos G., Atkin I., Drexler H.G., Kohara A.,
RA   MacLeod R.A.F., Masters J.R.W., Nakamura Y., Reid Y.A., Reddel R.R.,
RA   Freshney R.I.;
RT   "Check your cultures! A list of cross-contaminated or misidentified
RT   cell lines.";
RL   Int. J. Cancer 127:1-8(2010).